Due to the non-permanent occupation of JAK2 molecules with ruxolitinib, intermittent rebound activation of JAK2 downstream signaling might contribute to disease persistence and the limited anti-clonal effect observed in MPN patients treated with JAK1/2 inhibitors. Here, JAK2 is linked to myeloproliferative disorder.